Optimum timing of treatment for hepatitis C infection relative to liver transplantation

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 2, 2016, Pages 165-172

  Coilly, Audrey ^a,b,c   Roche, Bruno ^a,b,c   Duclos Vallée, Jean Charles ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; INTERFERON; LEDIPASVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CHEMOEMBOLIZATION; DRUG INTERACTION; DRUG TOLERANCE; GRAFT REJECTION; HEPATITIS C; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; REVIEW; CHRONIC HEPATITIS C; COMPLICATION; DRUG ADMINISTRATION; END STAGE LIVER DISEASE; PERIOPERATIVE PERIOD; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PERIOPERATIVE CARE; RECURRENCE; TREATMENT OUTCOME;

EID: 84996524370     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30008-5     Document Type: Review

References (52)

1. 1 Burra, P, Germani, G, Adam, R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol 58 (2013), 287–296.
2. 2 Neumann, UP, Berg, T, Bahra, M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004), 830–836.
3. 3 Forman, LM, Lewis, JD, Berlin, JA, Feldman, HI, Lucey, MR, The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002), 889–896.
4. 4 Berenguer, M, Prieto, M, Rayon, JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32 (2000), 852–858.
5. 5 Berenguer, M, Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49 (2008), 274–287.
6. 6 Carrion, JA, Martinez-Bauer, E, Crespo, G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 50 (2009), 719–728.
7. 7 Hézode, C, Fontaine, H, Dorival, C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147 (2014), 132–142 e4.
8. 8 Coilly, A, Dumortier, J, Botta-Fridlund, D, et al. Multicenter experience with boceprevir or telaprevir to treat hepatitis C recurrence after liver transplantation: when present becomes past, what lessons for future?. PLoS One, 10, 2015, e0138091.
9. 9 Coilly, A, Roche, B, Dumortier, J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 60 (2014), 78–86.
10. 10 Charlton, M, Gane, E, Manns, MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
11. 11 Kwo, PY, Mantry, PS, Coakley, E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 371 (2014), 2375–2382.
12. 12 Poordad, F, Schiff, ER, Vierling, JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology, 2016, 10.1002/hep.28446 published online March 7.
13. 13 Charlton, M, Everson, GT, Flamm, SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
14. 14 Manns, M, Samuel, D, Gane, EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16 (2016), 685–697.
15. 15 Brown, RS Jr, O'Leary, JG, Reddy, KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl 22 (2016), 24–33.
16. 16 Pungpapong, S, Aqel, B, Leise, M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886.
17. 17 Coilly, A, Fougerou, C, De Ledinghen, V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation—the CO23 ANRS CUPILT study. J Hepatol, 2016, 10.1016/j.jhep.2016.05.039 published online June 1.
18. 18 Fontana, RJ, Brown, RS Jr, Moreno-Zamora, A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 22 (2016), 446–458.
19. 19 Herzer, K, Papadopoulos-Kohn, A, Walker, A, et al. Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant. Digestion 91 (2015), 326–333.
20. 20 Forns, X, Charlton, M, Denning, J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
21. 21 Leroy, V, Dumortier, J, Coilly, A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 13 (2015), 1993–2001 e2.
22. 22 Narang, TK, Ahrens, W, Russo, MW, Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 16 (2010), 1228–1235.
23. 23 McCashland, TM, Retransplantation for recurrent hepatitis C: positive aspects. Liver Transpl 9:suppl (2003), S67–S72.
24. 24 Antonini, TM, Sebagh, M, Roque-Afonso, AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 11 (2011), 1686–1695.
25. 25 Pasulo, L, Di Benedetto, C, Mazzarelli, C, et al. Pre-emptive post-transplant HCV treatment with Ifn-free DAA: preliminary results from a pilot study. Transplantation, 48, 2016, e60.
26. 26 Houssel-Debry, P, Duvoux, C, Coilly, A, et al. Should we keep using ribavirin to treat HCV recurrence after liver transplantation?. J Hepatol, 64(suppl 2), 2016, S144 (abstr PS018).
27. 27 Curry, MP, Forns, X, Chung, RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107 e1.
28. 28 Foster, GR, Irving, WL, Cheung, MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
29. 29 Aqel, BA, Pungpapong, S, Leise, M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 62 (2015), 1004–1012.
30. 30 Coilly, A, Pageaux, GP, Houssel-Debry, P, et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs?. Hepatology, 62, 2015, 67A (abstr 95).
31. 31 Curry, MP, O'Leary, JG, Bzowej, N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
32. 32 Forns X BM, Berenguer M, Herzer K, et al. O004: on-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the phase II saturn study. J Hepatol 62 (suppl 2): S191–92.
33. 33 Coilly A for the The Cupilt Study Group. Effect of sofosbuvir/daclatasvir +/– ribavirin on the pharmacokinetics of calcineurin inhibitors in liver transplant recipients—from the ANRS CO23 CUPILT Study. Transplantation, 100(suppl 5), 2016 (abstr O-31).
34. 34 Anty, R, Coilly, A, Fougerou-Leurent, C, De Ledinghen, V, Duvoux, C, Di Martino, V, Renal dysfunction in liver transplant patients treated with sofosbuvir based-regimen for HCV recurrence: results from a large French prospective Multicentric ANRS CO23 CUPILT. Transplantation, 100(suppl 5), 2016, S92 (abstr S39).
35. 35 Merck. Highlights of prescribing information. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf (accessed July 25, 2016).
36. 36 Lawitz, E, Poordad, F, Gutierrez, J, et al. LP07: simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the phase II impact study. J Hepatol 62 (2015), S266–S267.
37. 37 US Food and Drug Administration. Hepatitis C treatments Viekira Pak and Technivie: drug safety communication—risk of serious liver injury. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm, Oct 22, 2015 (accessed July 5, 2016).
38. 38 Dyson, JK, Hutchinson, J, Harrison, L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 64 (2016), 234–238.
39. 39 Renet, S, Chaumais, MC, Antonini, T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology, 149, 2015, 1378 80.e1.
40. 40 Fontaine, H, Lazarus, A, Pol, S, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med 373 (2015), 1886–1888.
41. 41 Renard, S, Borentain, P, Salaun, E, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest 149 (2016), e69–e73.
42. 42 Savale, L, Chaumais, MC, Montani, D, et al. Direct-acting antiviral medications for hepatitis C virus infection and pulmonary arterial hypertension. Chest 150 (2016), 256–258.
43. 43 Pol, S, Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol, 2016, 10.1016/j.jhep.2016.05.04 published online June 7.
44. 44 Zhang, NLW, Liang, S, Neff, G, 276 outcomes in patients with hepatocellaular carcinoma and HCV infection treated with RFA and antiviral therapy. J Hepatol, 58, 2013, S117.
45. 45 Reig, M, Marino, Z, Perello, C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol, 2016, 10.1016/j.jhep.2016.04.008 published online April 12.
46. 46 Bruix, J, Gores, GJ, Mazzaferro, V, Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63 (2014), 844–855.
47. 47 Afdhal, N, Everson, JL, Calleja, G, et al. O68 Sofosbuvir and ribavirin for the treatment of chronic HCV With cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol, 60(suppl), 2014, S28 (abstr).
48. 48 Lens, S, Rincon, D, Garcia-Retortillo, M, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 13 (2015), 1846–1853 e1.
49. 49 Munoz, SJ, Reich, DJ, Rothstein, KD, Xiao, GS, Patel, V, McNulty, GL, Curing decompensated wait listed HCV patients with the new DAAs: the potential significant impact on liver transplant wait list and organ allocation. Hepatology, 62, 2015, 84A (abstr 202).
50. 50 Fernández-Carrillo, C, Lens, S, LLop, E, et al. Treatment of hepatitis C virus in patients with advances cirrhosis: always justified? Analysis of the HEPA-C Registry. J Hepatol, 64(suppl 2), 2016, S133 (abstr GS01).
51. 51 Belli, LS, Berenguer, M, Cortesi, PA, et al. Delisting of liver transplant candidates with chronic hepatitic C after viral eradication: a European study. J Hepatol, 2016, 10.1016/j.jhep.2016.05.010 published online May 17.
52. 52 Cheung, MCM, Foster, GR, Irving, WL, et al. Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/daclatasvir with or witouht ribavirin—6 and 12 months outcomes compared to untreated patients. J Hepatol, 64(suppl 2), 2016, S185 (abstr PS097).